Omicron breakthrough infections in patients with immune-mediated inflammatory diseases.
作者信息
Liew Jean W, Sattui Sebastian E
机构信息
Section of Rheumatology, Boston University School of Medicine, Boston, MA 02118, USA.
Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
出版信息
Lancet Rheumatol. 2022 Nov;4(11):e751-e752. doi: 10.1016/S2665-9913(22)00251-X. Epub 2022 Aug 23.
Abstract
摘要
相似文献
1
Omicron breakthrough infections in patients with immune-mediated inflammatory diseases.免疫介导性炎症疾病患者中的奥密克戎突破性感染
Lancet Rheumatol. 2022 Nov;4(11):e751-e752. doi: 10.1016/S2665-9913(22)00251-X. Epub 2022 Aug 23.
2
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.免疫介导的炎症性疾病患者中感染 SARS-CoV-2 奥密克戎（B.1.1.529）变异株的突破性感染。
Ann Rheum Dis. 2022 Dec;81(12):1757-1766. doi: 10.1136/ard-2022-222904. Epub 2022 Sep 5.
3
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.使用免疫抑制剂的免疫介导炎症性疾病的接种疫苗患者中出现的德尔塔（B.1.617.2）变异株导致的严重急性呼吸综合征冠状病毒2突破性感染：两项前瞻性队列研究的子研究
Lancet Rheumatol. 2022 Jun;4(6):e417-e429. doi: 10.1016/S2665-9913(22)00102-3. Epub 2022 Apr 29.
4
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period.在奥密克戎毒株占主导期间免疫介导性炎症疾病患者中的新型冠状病毒2型突破性感染
Lancet Rheumatol. 2022 Nov;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1. Epub 2022 Aug 23.
5
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.Omicron BA.1 变异株突破感染同源第三剂 Comirnaty® COVID-19 疫苗后的养老院居民：寻找保护相关因素。
J Med Virol. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. Epub 2022 May 25.
6
Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.评估中国广东省肇庆市未接种疫苗的个体和奥密克戎 BA.2 感染疫苗接种者针对 SARS-CoV-2 的抗体反应。
Virol J. 2022 Nov 25;19(1):197. doi: 10.1186/s12985-022-01912-0.
7
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
8
SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study.奥密克戎变异株逃避 mRNA 疫苗加强针诱导的自身免疫性风湿病患者抗体中和作用：一项观察性队列研究。
Ann Rheum Dis. 2022 Nov;81(11):1585-1593. doi: 10.1136/ard-2022-222689. Epub 2022 Jul 25.
9
A severe presentation of breakthrough infection caused by the Omicron variant with radiological findings of COVID-19 pneumonia in an elderly woman.一名老年女性因奥密克戎变异株导致突破性感染，出现了新冠肺炎肺炎的影像学表现。
Radiol Case Rep. 2022 Jul 12;17(9):3326-3330. doi: 10.1016/j.radcr.2022.06.034. eCollection 2022 Sep.
10
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.在日本，10 名感染 SARS-CoV-2 奥密克戎变异株突破性感染的患者的中和活性和抗体滴度。
J Infect Chemother. 2022 Sep;28(9):1340-1343. doi: 10.1016/j.jiac.2022.04.018. Epub 2022 Apr 22.
本文引用的文献
1
SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases during the omicron dominant period.在奥密克戎毒株占主导期间免疫介导性炎症疾病患者中的新型冠状病毒2型突破性感染
Lancet Rheumatol. 2022 Nov;4(11):e747-e750. doi: 10.1016/S2665-9913(22)00221-1. Epub 2022 Aug 23.
2
Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.替沙格韦单抗和西加韦单抗（Evusheld）用于 1112 例严重免疫功能低下患者的 COVID-19 暴露前预防。
Clin Microbiol Infect. 2022 Dec;28(12):1654.e1-1654.e4. doi: 10.1016/j.cmi.2022.07.015. Epub 2022 Aug 1.
3
Breakthrough SARS-CoV-2 Infections in Patients With Immune-Mediated Disease Undergoing B Cell-Depleting Therapy: A Retrospective Cohort Analysis.B 细胞耗竭治疗的免疫介导性疾病患者突破性 SARS-CoV-2 感染：一项回顾性队列分析。
Arthritis Rheumatol. 2022 Dec;74(12):1906-1915. doi: 10.1002/art.42287. Epub 2022 Oct 31.
4
Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022.按邮政编码划分的社会脆弱性程度开出的用于治疗 COVID-19 的口服抗病毒药物 - 美国，2021 年 12 月 23 日-2022 年 5 月 21 日。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):825-829. doi: 10.15585/mmwr.mm7125e1.
5
Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.替沙格韦单抗/西加韦单抗用于暴露前预防，可降低奥密克戎变异株流行期间接受疫苗接种的实体器官移植受者突破性感染的风险。
Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.
6
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform.与免疫介导的炎症性疾病和免疫调节疗法相关的重症 COVID-19 结局风险：OpenSAFELY 平台的一项全国性队列研究
Lancet Rheumatol. 2022 Jul;4(7):e490-e506. doi: 10.1016/S2665-9913(22)00098-4. Epub 2022 Jun 9.
7
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies.使用免疫抑制剂的免疫介导炎症性疾病的接种疫苗患者中出现的德尔塔（B.1.617.2）变异株导致的严重急性呼吸综合征冠状病毒2突破性感染：两项前瞻性队列研究的子研究
Lancet Rheumatol. 2022 Jun;4(6):e417-e429. doi: 10.1016/S2665-9913(22)00102-3. Epub 2022 Apr 29.
8
Disparities in COVID-19 Monoclonal Antibody Delivery: a Retrospective Cohort Study.COVID-19 单克隆抗体治疗的差异：一项回顾性队列研究。
J Gen Intern Med. 2022 Aug;37(10):2505-2513. doi: 10.1007/s11606-022-07603-4. Epub 2022 Apr 25.
9
Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.腰带与吊带：疫苗和替沙格韦单抗/西加韦单抗在免疫功能低下患者中预防 COVID-19 的应用。
Ann Intern Med. 2022 Jun;175(6):892-894. doi: 10.7326/M22-1026. Epub 2022 Apr 12.
10
Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.美国 SARS-CoV-2 疫苗接种后免疫功能障碍与 COVID-19 突破性感染的关联。
JAMA Intern Med. 2022 Feb 1;182(2):153-162. doi: 10.1001/jamainternmed.2021.7024.
Zotero 插件